Objective:

To highlight recently published research by Dana-Farber faculty from March 1 - 15, 2026, emphasizing its significance in advancing cancer treatment.

Approach:

Key Findings:

• MTAP loss is frequent in oncogene-driven NSCLC, particularly in ALK-, RET-, and EGFR-altered subtypes, suggesting a potential target for therapy.
• Nivolumab plus ipilimumab showed significant long-term survival benefits over sunitinib in advanced renal cell carcinoma, reinforcing its role as a first-line treatment.
• Orca-T achieved superior chronic GVHD-free survival compared to conventional grafts, indicating a promising advancement in transplant techniques.

Interpretation:

MTAP loss may confer sensitivity to PRMT5 inhibitors in NSCLC, while Nivolumab plus ipilimumab remains a standard of care in advanced RCC, highlighting the need for ongoing research into targeted therapies. Orca-T shows promise in reducing chronic GVHD, potentially transforming transplant protocols.

Limitations:

• MTAP loss did not significantly impact response or overall survival in treated NSCLC, suggesting the need for further investigation into its clinical relevance.
• Limited follow-up in the Orca-T trial may affect long-term outcome assessments, necessitating additional studies to confirm findings.

Conclusion:

The findings underscore the potential of targeted therapies in specific cancer subtypes and the importance of innovative graft manipulation techniques in transplant settings, paving the way for future research and clinical applications.

Source

Based on findings from:

Dana-Farber Research News 04.01.2026

Dana-Farber, 2026.

https://physicianresources.dana-farber.org/news/dana-farber-research-news-04-01-2026

Attribution Notice

This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.